Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Feb;6(2):101-112.
doi: 10.1159/000452138. Epub 2016 Dec 15.

Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives

M Kudo  1
Affiliations
Editorial

Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives

M Kudo. Liver Cancer. 2017 Feb.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The cancer-immunity cycle. Naïve T cells are activated by signals from antigen-presenting cells (APCs), which recognize the cancer cell antigens in the lymph node. At the tumor, activated T cells attack the cancer cells. CTLs, cytotoxic T lymphocytes.
Fig. 2
Fig. 2
After the recognition of tumor-associated antigen (TAA) by the T-cell receptor (TCR), a co-stimulatory signal by binding B7 and CD28, naïve T cells are activated. Consequently, the activated T cells attack the cancer cells by recognizing the TAA. Cancer cells are killed by activated T cells by producing perforin and granzyme. APC, antigen-presenting cell.
Fig. 3
Fig. 3
The immune checkpoint molecules PD-1, PD-L1, and CTLA-4 play an impact role in the cancer's escape from activated T cells (cancer immunotolerance/escape). APC, antigen-presenting cell; TAA, tumor-associated antigen; TCR, T-cell receptor.
Fig. 4
Fig. 4
Anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies restore T-cell activation, leading to an effective cancer attack by the immune system. APC, antigen-presenting cell; TAA, tumor-associated antigen; TCR, T-cell receptor; CTL, cytotoxic T lymphocyte.
None
See this image and copyright information in PMC

References

    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
    1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. - PubMed
    1. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM, STORM Investigators Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354. - PubMed
    1. Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H, Peretinoin Study Group Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2015;50:191–202. - PMC - PubMed
    1. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117–2127. - PubMed

Publication types

LinkOut - more resources